Binds A Receptor (e.g., Transferrin Receptor, Fc Receptor, Dihydropyridine Receptor, Il-2 Receptor, Etc.) Patents (Class 435/334)
-
Publication number: 20140219919Abstract: The present disclosure provides proteins comprising antigen binding sites of antibodies that bind to interleukin-11 (IL-11) receptor alpha (IL-11R?) and uses thereof, e.g., in therapy.Type: ApplicationFiled: February 6, 2014Publication date: August 7, 2014Applicant: CSL LimitedInventors: Kirsten EDWARDS, Matthew HARDY, Veronika RAYZMAN, Michael WILSON
-
Publication number: 20140212439Abstract: The present invention provides an antibody which recognizes an epitope recognized by an antibody produced by a hybridoma SH348-1 (FERM BP-10836) or a hybridoma SH357-1 (FERM BP-10837), an antibody produced by the hybridoma SH348-1 or the hybridoma SH357-1, an antibody obtained by humanizing the antibody produced by the hybridoma SH348-1 or the hybridoma SH357-1, a pharmaceutical agent comprising the antibody as an active ingredient, etc.Type: ApplicationFiled: May 22, 2013Publication date: July 31, 2014Applicant: Daiichi Sankyo Company, LimitedInventors: Jun Hasegawa, Toshiaki Ohtsuka, Atsushi Urano, Junko Yamaguchi, Toshinori Agatsuma, Kaori Nakahara, Takeshi Takizawa
-
Patent number: 8790663Abstract: Provided are antigenic determinants of human death receptor DR5. The antigenic determinants have the amino acid sequence of LITQQDLAPQQRA (SEQ ID No. 7), wherein the core polypeptide is QDLAP (SEQ ID No. 1). The polypeptides comprising said antigenic determinants can activate the signal pathway downstream of DR5 after binding to monoclonal antibody AD5-10, then result in apoptosis. The antigenic determinants can be used for screening and preparing anti-human DR5 agonistic antibody, small molecular compound binding to DR5 and DR5 vaccine.Type: GrantFiled: April 3, 2009Date of Patent: July 29, 2014Assignee: Institute of Basic Medical Sciences, Chinese Academy of Medical SciencesInventors: Yanxin Liu, Peng Zhang, Yong Zheng, Dexian Zheng
-
Patent number: 8790649Abstract: Novel anti-cancer agents, including, but not limited to, antibodies and immunoconjugates, that bind to EGFR are provided. Methods of using the agents, antibodies, or immunoconjugates, such as methods of inhibiting tumor growth are further provided.Type: GrantFiled: October 28, 2011Date of Patent: July 29, 2014Assignee: ImmunoGen, Inc.Inventors: Julianto Setiady, Peter U. Park, Lingyun Rui, Thomas Chittenden, Gillian Payne
-
Publication number: 20140205610Abstract: The present invention provides an anti-human FOLR1 antibody against diseases associated with human FOLR1-expressing cells, which specifically recognizes and binds to an amino acid sequence of human FOLR1 or a conformational structure thereof and also has a high effector activity such as antibody-dependent cellular cytotoxicity activity (ADCC activity). The present invention can provide a monoclonal antibody which specifically recognizes and binds to the amino acid sequence of human FOLR1 or the conformational structure thereof and also has ADCC activity and CDC activity, or an antibody fragment thereof, a DNA encoding the antibody, a vector comprising the DNA, a transformant obtained by introducing the vector, a method for producing the antibody or the antibody fragment thereof using the transformant, and a therapeutic agent and a diagnostic agent comprising the antibody or the antibody fragment as an active ingredient.Type: ApplicationFiled: November 25, 2013Publication date: July 24, 2014Applicant: KYOWA HAKKO KIRIN CO., LTDInventors: Munetoshi ANDO, Hiroshi ANDO, Mariko NAKANO, Naoya KAMEYAMA, Tsuguo KUBOTA
-
Publication number: 20140193431Abstract: Disclosed are a human antibody comprising a human complementarity-determining region (CDR), which binds specifically to c-Met, and a framework region (FR), a polynucleotide encoding the human antibody, an expression vector comprising the polynucleotide, a transformant transformed with the expression vector, a method of producing the human antibody B7 by culturing the transformant, a wound healing composition comprising the human antibody as an active ingredient, a cell regeneration composition comprising the antibody as an active ingredient, and a drug conjugate comprising a drug linked to the human antibody. The c-Met-specific human antibody can function as an HGF mimic that can be used as a wound healing composition. The antibody can be widely used to determine the treatment and prognosis of various diseases, including neuronal infarction, progressive nephropathy, liver cirrhosis, lung fibrosis, kidney injury, liver injury, lung injury, and ulcerative wounds, which are treated by activation of HGF or c-Met.Type: ApplicationFiled: June 4, 2012Publication date: July 10, 2014Applicant: Korea Research Institute of Bioscience and BiotechnologyInventors: Young Woo Park, KiWon Jo, Chan Woong Park, Seok Ho Yoo, Myeoung Hee Jang, Hye Nan Kim, Seon Ha Yun, Kyu Won Cho, Mi Ra Park
-
Publication number: 20140170159Abstract: Provided herein are modified anti-EGFR antibodies and nucleic acid molecules encoding modified anti-EGFR antibodies. Also provided are methods of treatment and uses using modified anti-EGFR antibodies.Type: ApplicationFiled: March 8, 2013Publication date: June 19, 2014Inventors: Ge Wei, Gregory I. Frost, Lei Huang, H. Michael Shepard, Daniel Edward Vaughn
-
Publication number: 20140170681Abstract: The present invention provides a novel, isolated anti-CXCR4 antibody for use in the diagnosis of cancer.Type: ApplicationFiled: July 30, 2012Publication date: June 19, 2014Inventors: Christine Klinguer-Hamour, Alexandra Jouhanneaud, Marie-Claire Janin-Bussat
-
Publication number: 20140154268Abstract: The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies, or antigen binding portions thereof, that specifically bind to integrin ?5?1 with high affinity. Nucleic acid molecules encoding the antibodies of the disclosure, expression vectors, host cells and methods for expressing the antibodies of the disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies or antigen binding portions thereof are also provided. The disclosure also provides methods for treating various cancers using the anti-?5?1 antibodies or antigen binding portions thereof described herein.Type: ApplicationFiled: February 21, 2013Publication date: June 5, 2014Applicants: PFIZER INC., BRISTOL-MYERS SQUIBB COMPANYInventors: STEVEN LEE BENDER, GERALD FRIES CASPERSON, DANA DAN HU-LOWE, XIN JIANG, GANG LI, MICHAEL AIDAN NORTH, JIANYING WANG, GRANT WICKMAN, PETER BRAMS, HAICHUN HUANG, BRIGITTE DEVAUX, HAIBIN CHEN, DAWN M. TANAMACHI, KRISTOPHER TOY, LAN YANG, TIM W. SPROUL, MARK YAMANAKA
-
Publication number: 20140154267Abstract: Methods for treating medical conditions induced by interleukin-4 involve administering an IL-4 antagonist to a patient afflicted with such a condition. Suitable IL-4 antagonists include, but are not limited to, IL-4 receptors (such as a soluble human IL-4 receptor), antibodies that bind IL-4, antibodies that bind IL-4R, IL-4 muteins that bind to IL-4R but do not induce a biological response, molecules that inhibit IL-4-induced signal transduction, and other compounds that inhibit a biological effect that results from the binding of IL-4 to a cell surface IL-4R. Particular antibodies provided herein include human monoclonal antibodies generated by procedures involving immunization of transgenic mice. Such human antibodies may be raised against human IL-4 receptor. Certain of the antibodies inhibit both IL-4-induced and IL-13-induced biological activities.Type: ApplicationFiled: February 7, 2014Publication date: June 5, 2014Applicant: Immunex CorporationInventors: Richard J. ARMITAGE, Jose Carlos ESCOBAR, Arvia E. MORRIS, John D. PLUENNEKE
-
Patent number: 8741586Abstract: The present invention relates to a method of diagnosis and therapy of cancers expressing the HER2 receptor. The invention provides antibodies or fragments thereof that recognise an epitope of the HER2 receptor truncated form CTF-611, said epitope being defined by a sequence included in SEQ ID NO: 2, and that are capable of discriminating between CTF-611 and CTF-616 (represented by SEQ ID NO:7), preferably additionally capable of discriminating between CTF-611 and CTF-613 (represented by SEQ ID NO:6). The invention also provides a method of cancer diagnosis using the disclosed antibodies, which comprises the detection of the presence of the HER2 receptor truncated form consisting of the amino acid sequence SEQ ID NO: 1 in a patient sample.Type: GrantFiled: December 6, 2010Date of Patent: June 3, 2014Assignees: Fundacio Privada Institucio Catalana de Recerca i Estudis Avancats, Fundacio Privada Institut d'Investigacio Oncologica de vall d'HebronInventors: Joaquin Arribas Lopez, Kim Pedersen, Pier-Davide Angellini, Josep Lluis Parra Palau, Jose Baselga Torres
-
Publication number: 20140147450Abstract: The present invention relates to antibodies and antigen binding fragments thereof which bind to the human CD70 protein with high affinity and display potent inhibition of tumour cell growth.Type: ApplicationFiled: November 6, 2013Publication date: May 29, 2014Applicant: ARGEN-X B.V.Inventors: Karen SILENCE, Peter ULRICHTS, Johannes Joseph Wilhelmus DE HAARD, Torsten DREIER, Michael John Scott SAUNDERS, Harald WAJANT, Sofie Maria Elvire GABRIELS, Mahan MOSHIR
-
Patent number: 8734794Abstract: A fully humanized antibody having binding specificity to Toll-like Receptor 2 comprises a light chain and a heavy chain entirely comprised of amino acid sequence of human origin. The variable region of the light chain comprises an amino acid sequence which is substantially homologous with the sequence of SEQ ID NO:1, while the variable region of the heavy domain comprises an amino acid sequence which is substantially homologous with the sequence of SEQ ID NO:4. Also provided are nucleic acids encoding such antibodies, as well as the use of the antibodies in medicine, in particular for the treatment of inflammatory and autoimmune diseases which are mediated by Toll-like Receptor 2 activation and signalling.Type: GrantFiled: July 6, 2010Date of Patent: May 27, 2014Assignee: Opsona Therapeutics LimitedInventor: Jerome Dellacasagrande
-
Patent number: 8735095Abstract: The present invention provides nucleic acid molecules that encode antibodies or antigen-binding fragments thereof, which specifically bind human interleukin-4 receptor (IL-4R). Also provided are expression vectors comprising nucleic acid molecule that encode anti-IL-4R antibodies, host cells comprising the expression vectors, and methods of producing anti-IL-4R antibodies or antigen-binding fragments thereof comprising growing the host cells under conditions permitting production of the antibody or fragment, and recovering the antibody or fragment so produced.Type: GrantFiled: November 16, 2012Date of Patent: May 27, 2014Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Joel H. Martin, Tammy T. Huang, Jeanette L. Fairhurst, Nicholas J. Papadopoulos
-
Publication number: 20140141019Abstract: The invention relates to antibodies against HER3 and their use in the treatment of cancer.Type: ApplicationFiled: May 11, 2012Publication date: May 22, 2014Applicant: INSERM (INSTITUT NATIONALDE LA SENTE ET DE LA RECHERCHE MEDICALE)Inventors: Abdelhakim Kharrat, Olivier Dubreuil, Yassamine Lazrek, Philippe Mondon, Khalil Bouayadi, Thierry Chardes, Andre Pelegrin, Christel Larbouret, Nadege A. Gaborit
-
Patent number: 8728740Abstract: Epitopes localized on FNIII-8 repeat that are normally cryptic but are unmasked by insertion of FNIII-B into the FN molecule and are recognized by specific ligands are described; antibodies or their fragments able to identify the above said epitope are also described.Type: GrantFiled: December 11, 2009Date of Patent: May 20, 2014Assignee: Sirius-Biotech S.R.L.Inventors: Patrizia Castellani, Francesca Sassi, M. Barbara Carnemolla, Laura Borsi, Enrica Balza
-
Patent number: 8722400Abstract: The invention relates to novel artificial antigen presenting cells (aAPCs). The aAPC comprises at least one stimulatory ligand and at least one co-stimulatory ligand where the ligands each specifically bind with a cognate molecule on a T cell of interest, thereby mediating expansion of the T cell. The aAPC of the invention can further comprise additional molecules useful for expanding a T cell of interest. The aAPC of the invention can be used as an “off the shelf” APC that can be readily designed to expand a T cell of interest. Also, the aAPC of the invention can be used identify the stimulatory, co-stimulatory, and any other factors that mediate growth and expansion of a T cell of interest. Thus, the present invention provides powerful tools for development of novel therapeutics where activation and expansion of a T cell can provide a benefit.Type: GrantFiled: June 8, 2010Date of Patent: May 13, 2014Assignee: The Trustees of the University of PennsylvaniaInventors: James L. Riley, Carl H. June, Robert H. Vonderheide, Nicole Aqui, Megan M. Suhoski
-
Publication number: 20140127223Abstract: A monoclonal antibody that binds to an extracellular domain of human receptor-type protein tyrosine phosphatase ? (human PTPRS), or a fragment including an antigen-binding region thereof.Type: ApplicationFiled: April 27, 2012Publication date: May 8, 2014Applicant: SBI BIOTECH CO., LTD.Inventors: Tomohide Yamazaki, Jing Zhao, Koji Ishida, Yasue Shibata, Minkwon Cho, Mayuki Endo
-
Publication number: 20140127236Abstract: The present invention relates to novel humanised antibodies against human CD52 and their use in methods of treating or preventing human diseases.Type: ApplicationFiled: June 1, 2012Publication date: May 8, 2014Applicant: ANTITOPE LIMITEDInventors: Timothy David JONES, Robert George Edward Holgate, Francis Joseph Carr
-
Patent number: 8715668Abstract: An antibody of the invention interacts with human DR5 to produce agonistic or antagonistic effects downstream of the receptor including inhibition of cell proliferation and apoptosis. Nucleic acid sequences and amino acid sequences of anti-DR5 antibodies have been elucidated and vectors and cells containing and expressing these sequences have been generated. Methods and uses for the antibodies are detailed including treatment of apoptosis-related disease and treatment of dysregulated cell growth.Type: GrantFiled: September 17, 2012Date of Patent: May 6, 2014Assignee: The UAB Research FoundationInventors: Tong Zhou, Kimihisa Ichikawa, Robert P. Kimberly, William J. Koopman
-
Publication number: 20140120089Abstract: The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to insulin-like growth factor I receptor (IGF-IR), which is preferably human IGF-IR. The invention also relates to human anti-IGF-IR antibodies, including chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulin molecules derived from anti-IGF-IR antibodies and nucleic acid molecules encoding such molecules. The present invention also relates to methods of making anti-IGF-IR antibodies, pharmaceutical compositions comprising these antibodies and methods of using the antibodies and compositions thereof for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-IGF-IR antibodies.Type: ApplicationFiled: December 19, 2013Publication date: May 1, 2014Applicants: PFIZER INC., AMGEN FREMONT INC.Inventors: Bruce D. Cohen, Jean Beebe, Jr., Penelope E. Miller, James D. Moyer, Jose Ramon Corvalan, Michael Gallo
-
Publication number: 20140115727Abstract: The invention relates to a novel antibody capable of binding specifically to the human c-Met receptor and/or capable of specifically inhibiting the tyrosine kinase activity of said receptor both in a ligand-dependent and in a ligand-independent manner, with an improved antagonistic activity, said antibody comprising a modified hinge region. The invention also relates to a composition comprising such an antibody antagonist to c-Met and its use as a medicament for treating cancer.Type: ApplicationFiled: August 29, 2013Publication date: April 24, 2014Applicant: Pierre Fabre MedicamentInventors: Liliane Goetsch, Thierry Wurch, Cedric Bes
-
Publication number: 20140112926Abstract: Disclosed are Fc-containing proteins comprising a binding region and a variant Fc region that can elicit one or more immune effector function and/or bind to an Fc receptor more effectively than a similar Fc-containing protein comprising a wild type Fc region. Also disclosed are nucleic acids encoding such Fc-containing proteins, methods for making such proteins, and methods of treatment utilizing such proteins.Type: ApplicationFiled: March 15, 2012Publication date: April 24, 2014Applicant: AMGEN INC.Inventors: Zhi Liu, Gunasekaran Kannan, Wei Yan
-
Publication number: 20140112942Abstract: The invention relates to a binding compound, which binds the same epitope of human CD27 as monoclonal antibody hCD27.15, produced by hybridoma hCD27.15 which was deposited with the ATCC in on Jun. 2, 2010 under number PTA-11008. In particular the invention relates to such a binding compound of claim 1 which may comprise: an antibody heavy chain variable region which may comprise at least one CDR selected from the group consisting of SEQ ID NOs: 5, 6 and 7, or a variant of any of said sequences; and/or an antibody light chain variable region which may comprise at least one CDR selected from the group consisting of SEQ ID NOs: 8, 9 and 10, or a variant of any of said sequences.Type: ApplicationFiled: March 11, 2013Publication date: April 24, 2014Applicant: BIONOVION HOLDING B.V.Inventors: Hans Van Eenennaam, Winfried Robert Mulder, Jannetje Geertruida Borst, Aartje Maria Elizabeth Veraar, Paul Maria Frederikus Vink
-
Publication number: 20140112931Abstract: The present invention provides for isolated anti-human-HER3 antibodies or fragments thereof. More particularly the present invention provides an isolated monoclonal antibody that specifically binds to the extracellular domain of HER-3 and competes for binding to the extracellular domain of human HER-3 with the antibody produced obtainable from hybridoma deposited as CNCM-I-4486. The antibodies described in the present invention are useful for the treatment of cancer.Type: ApplicationFiled: May 21, 2012Publication date: April 24, 2014Applicants: UNIVERSITE DE MONTPELLIER 1, CENTRE VAL D'AURELLE - PAUL LAMARQUEInventors: Thierry Chardes, Andre Pelegrin, Christel Larbouret, Nadege Gaborit, Yassamine Lazrek
-
Publication number: 20140105914Abstract: The invention provides an anti-CTLA4 antibody which inhibits the binding of CTLA4 to human B7, in particular, it inhibits binding of CTLA4 to human B7.1 and/or human B7.2. Specific antibodies are provided with specific variable region sequences as well as compositions comprising such antibodies for use in treating disease.Type: ApplicationFiled: March 9, 2012Publication date: April 17, 2014Applicant: ANTITOPE LIMITEDInventors: Timothy David Jones, Robert George Edward Holgate, Francis Joseph Carr
-
Patent number: 8697664Abstract: Targeted binding agents directed to the antigen PDGFR-alpha and uses of such agents are disclosed herein. More specifically the invention relates to fully human monoclonal antibodies directed to the antigen PDGFR-alpha and uses of these antibodies. Aspects of the invention also relate to hybridomas or other cell lines expressing such antibodies. The described targeted binding agents and antibodies are useful as diagnostics and for the treatment of diseases associated with the activity and/or overexpression of PDGFR-alpha.Type: GrantFiled: February 18, 2010Date of Patent: April 15, 2014Assignee: MedImmune LimitedInventors: Naomi Laing, Jaspal Singh Kang, Ian Foltz, Gadi Gazit-Bornstein, Xiao-Dang Yang, Sue A. Cartlidge, David Charles Blakey
-
Publication number: 20140099708Abstract: The present invention relates to antibodies that specifically bind to IL12R?1, the non-signal transducing chain of both the heterodimeric IL12 and IL23 receptors. The invention more specifically relates to specific antibodies that are IL12 and IL23 receptor antagonists capable of inhibiting IL12/IL18 induced IFN? production of blood cells and compositions and methods of use for said antibodies to treat pathological disorders that can be treated by inhibiting IFN? production, IL12 and/IL23 signaling, such as rheumatoid arthritis, psoriasis or inflammatory bowel diseases or other autoimmune and inflammatory disorders.Type: ApplicationFiled: October 3, 2013Publication date: April 10, 2014Applicant: NOVARTIS AGInventors: Jose M. CARBALLIDO HERRERA, Stefan HARTLE, Christoph HEUSSER, Ingo KLAGGE, Andrea POLZER, Christoph SCHWAERZLER, Gabriela WOCHNIK-VELTRUP
-
Publication number: 20140099332Abstract: The invention generally relates to antibodies that bind to human folate receptor 1 and diagnostic assays for folate receptor 1-based therapies. Methods of using the antibodies to monitor therapy are further provided.Type: ApplicationFiled: August 30, 2013Publication date: April 10, 2014Inventors: NATHAN E. TESTA, CHRISTINA N. CARRIGAN, OLGA AB, DANIEL TAVARES, BENI B. WOLF
-
Patent number: 8691531Abstract: The present invention is directed to compositions of matter comprising nucleic acids encoding a polypeptide comprising the amino acid sequence of SEQ ID NO: 207 or 208, encoding an anti-CD79b antibody comprising the heavy chain variable domain sequence of SEQ ID NO: 207 and the light chain variable domain sequence of SEQ ID NO: 208, or encoding an anti-CD79b antibody having : (i) a variable light chain comprising a HVR-L1 having the sequence of SEQ ID NO: 194, a HVR-L2 having the sequence of SEQ ID NO: 195, and a HVR-L3 having the sequence of SEQ ID NO: 196 and (ii) a variable light chain comprising a HVR-H1 having the sequence of SEQ ID NO: 202, a HVR-H2 having the sequence of SEQ ID NO: 203, and a HVR-H3 having the sequence of SEQ ID NO: 204, and vectors and host cells thereof.Type: GrantFiled: November 28, 2011Date of Patent: April 8, 2014Assignee: Genentech, Inc.Inventors: Yvonne Chen, Mark Dennis, David Dornan, Kristi Elkins, Jagath Reddy Junutula, Andrew Polson, Bing Zheng
-
Patent number: 8686121Abstract: A method of diagnosing B-CLL in a subject in need thereof is provided. The method comprising determining in a biological sample of the subject a level of CD84 isoform C (SEQ ID NO: 30), wherein an increase in the level of the CD84 isoform C (SEQ ID NO: 30) beyond a predetermined threshold with respect to a level of the CD84 in a biological sample from a healthy individual is indicative of the B-CLL.Type: GrantFiled: September 23, 2009Date of Patent: April 1, 2014Assignee: Yeda Research and Development Co. Ltd.Inventors: Idit Shachar, Inbal Binsky, Mirko Sobotta
-
Publication number: 20140065168Abstract: Provided herein, in one aspect, are antibodies that immunospecifically bind to a human KIT antigen comprising the fourth and/or fifth extracellular Ig-like domains (that is, D4 and/or D5 domains), polynucleotides comprising nucleotide sequences encoding such antibodies, and expression vectors and host cells for producing such antibodies. The antibodies can inhibit KIT activity, such as ligand-induced receptor phosphorylation. Also provided herein are kits and pharmaceutical compositions comprising antibodies that specifically bind to a KIT antigen, as well as methods of treating or managing a KIT-associated disorder or disease and methods of diagnosing a KIT-associated disorder or disease using the antibodies described herein.Type: ApplicationFiled: July 24, 2013Publication date: March 6, 2014Applicant: KOLLTAN PHARMACEUTICALS, INC.Inventors: Yaron Hadari, Elizabeth M Mandel-Bausch, Francis Joseph Carr, Timothy David Jones, Laura Clare Alexandra Perry
-
Publication number: 20140056921Abstract: Hepatocyte growth factor (HGF) receptor antagonists are provided. The HGF receptor antagonists include HGF receptor antibodies and fragments thereof. The HGF receptor antagonists can be employed to block binding of HGF to HGF receptors or substantially inhibit HGF receptor activation. The HGF receptor antagonists may be included in pharmaceutical compositions, articles of manufacture, or kits. Methods of treating cancer using the HGF receptor antagonists are also provided.Type: ApplicationFiled: June 6, 2013Publication date: February 27, 2014Applicant: Genentech, Inc.Inventors: Ralph H. Schwall, Kelly H. Tabor
-
Patent number: 8652843Abstract: Disclosed are DDR1 binding agents and methods of using the agents for treating diseases such as cancer. The disclosure provides antibodies that specifically bind to an extracellular domain of DDR1 and modulate DDR1 activity. The disclosure further provides methods of using agents that modulate the activity of DDRI, such as antibodies that specifically bind DDR1, to reduce the tumorigenicity of tumors comprising cancer stem cells by reducing the frequency or number of cancer stem cells in the tumor. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer.Type: GrantFiled: August 12, 2009Date of Patent: February 18, 2014Assignee: OncoMed Pharmaceuticals, Inc.Inventors: Austin L. Gurney, Edward Thein Htun Van Der Horst, Sanjeev H. Satyal
-
Publication number: 20140037624Abstract: The invention provides anti-FGFR4 antibodies and methods of using the same.Type: ApplicationFiled: October 4, 2013Publication date: February 6, 2014Applicant: GENENTECH, INC.Inventors: Mark Dennis, Luc Desnoyer, Dorothy French
-
Publication number: 20140039165Abstract: The present inventors successfully obtained anti-NR10 antibodies having an effective neutralizing activity against NR10. The anti-NR10 antibodies provided by the present invention are useful as, for example, pharmaceuticals for treating or preventing inflammatory diseases.Type: ApplicationFiled: October 7, 2013Publication date: February 6, 2014Applicant: CHUGAI SEIYAKU KABUSHIKI KAISHAInventors: Taichi Kuramochi, Keiko Kasutani, Souhei Ohyama, Hiroyuki Tsunoda, Tomoyuki Igawa, Tatsuhiko Tachibana, Hirotake Shiraiwa, Keiko Esaki
-
Patent number: 8642037Abstract: The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to insulin-like growth factor I receptor (IGF-IR), which is preferably human IGF-IR. The invention also relates to human anti-IGF-IR antibodies, including chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulin molecules derived from anti-IGF-IR antibodies and nucleic acid molecules encoding such molecules. The present invention also relates to methods of making anti-IGF-IR antibodies, pharmaceutical compositions comprising these antibodies and methods of using the antibodies and compositions thereof for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-IGF-IR antibodies.Type: GrantFiled: June 27, 2011Date of Patent: February 4, 2014Assignees: Amgen Fremont Inc., Pfizer Inc.Inventors: Bruce D. Cohen, Jean Beebe, Penelope E. Miller, James D. Moyer, Jose Ramon Corvalan, Michael Gallo
-
Patent number: 8637022Abstract: The invention provides functionalized polypeptides, especially therapeutic polypeptides (e.g., scFv), comprising a linker sequence that can be rapidly and specifically functionalized by the addition of one or functional moieties (e.g., PEG) or binding specificities (e.g., an amino acid sequence with a particular binding specificity). Such functionalized polypeptides are advantageous in that they have improved pharmacokinetic properties (e.g., improved in vivo half-life, tissue penetration and tissue residency time) over non-functionalized polypeptides. Methods for the rapid and reproducible generation of functionalized polypeptides are also provided.Type: GrantFiled: June 30, 2009Date of Patent: January 28, 2014Assignee: ESBATech, an Alcon Biomedical Research Unit LLCInventor: David Urech
-
Publication number: 20140023662Abstract: Novel anti-cancer agents, including, but not limited to, antibodies and immunoconjugates, that bind to EGFR are provided. Methods of using the agents, antibodies, or immunoconjugates, such as methods of inhibiting tumor growth are further provided.Type: ApplicationFiled: October 28, 2011Publication date: January 23, 2014Applicant: ImmunoGen, Inc.Inventors: Julianto Setiady, Rajeeva Singh, Peter U. Park, Lingyun Rui, Thomas Chittenden
-
Publication number: 20140011271Abstract: The present invention relates to compositions and methods for characterizing, diagnosing, and treating cancer. In particular the invention provides the means and methods for the diagnosis, characterization, prognosis and treatment of cancer and specifically targeting cancer stem cells. The present invention provides an antibody that specifically binds to a non-ligand binding membrane proximal region of the extracellular domain of a human Notch receptor and inhibits tumor growth. The present invention further provides a method of treating cancer, the method comprising administering a therapeutically effective amount of an antibody that specifically binds to a non-ligand binding membrane proximal region of the extracellular domain of a human Notch receptor protein and inhibits tumor growth.Type: ApplicationFiled: March 13, 2013Publication date: January 9, 2014Applicant: OncoMed Pharmaceuticals, Inc.Inventors: Austin L. Gurney, Timothy Charles Hoey, Maureen Fitch Bruhns, Fumiko Takada Axelrod
-
Patent number: 8623353Abstract: The present invention is directed to a cross-reactive antibody that specifically inhibits or blocks mammalian Toll-like receptor 2 (TLR2)-mediated immune cell activation. The invention is further directed to an isolated nucleic acid or vector coding for the variable regions of the heavy and/or light chain of such an antibody. Also provided is a pharmaceutical composition comprising such an antibody, or a nucleic acid or vector encoding it. Further provided are methods of use of such compositions in the prevention and/or treatment of inflammatory processes or any other process induced by bacterial infection, trauma, or chronic inflammation, or for the prevention and/or treatment of bacteriaemia or sepsis.Type: GrantFiled: September 23, 2004Date of Patent: January 7, 2014Assignees: Technische Universitat Munchen, Amgen Inc.Inventors: Carsten Juergen Kirschning, Guangxun Meng, Hermann Wagner
-
Publication number: 20140004119Abstract: There are provided herein novel monoclonal antibodies that selectively bind and/or activate TrkC receptors, pharmaceutical compositions thereof and the use thereof for treating or preventing conditions which require activation of TrkC, such as amyotrophic lateral sclerosis and other neurodegenerative conditions and motor neuron diseases. The monoclonal antibodies are useful to screen for agents that share the same binding epitope on the TrkC receptor.Type: ApplicationFiled: November 30, 2010Publication date: January 2, 2014Applicants: THE UNIVERSITY OF BRITISH COLUMBIA, THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING / MCGILL UNIVERSITYInventors: Horacio Uri Saragovi, Véronique Guillemard, Neil Cashman
-
Publication number: 20130336992Abstract: Disclosed are specific binding agents, such as fully human antibodies, that bind to angiopoietin 1 and/or angiopoietin-2. Also disclosed are heavy chain fragments, light chain fragments, and CDRs of the antibodies, as well as methods of making and using the antibodies.Type: ApplicationFiled: August 26, 2013Publication date: December 19, 2013Applicant: AMGEN INC.Inventors: Thomas Charles Boone, Jonathan Daniel Oliner, Eunkyung Lee
-
Publication number: 20130330350Abstract: Provided in some embodiments are antibodies comprising a heavy chain having no native interchain cysteine amino acids, a light chain having no native interchain cysteine amino acids, and having no native interchain disulphide linkages between the heavy chain and the light chain. Also provided in certain embodiments are antibodies comprising a heavy chain having no native interchain cysteine amino acids, a light chain having no native interchain cysteine amino acids, and having no native interchain disulphide linkages between the heavy chain and the light chain where the native interchain cysteine amino acids have been replaced by amino acids having no thiol moiety.Type: ApplicationFiled: November 8, 2011Publication date: December 12, 2013Applicant: MedImmune, LLCInventor: Nazzareno Dimasi
-
Publication number: 20130330362Abstract: A humanized anti-EGFR antibody L4-H3 and gene encoding the antibody are disclosed. The antibody is composed of a heavy chain and a light chain. The amino acid sequence of the heavy chain variable region is shown as positions 1-145 of SEQ ID NO: 3, the heavy chain constant region is the heavy chain constant region of the human antibody IgG1, and the amino acid sequence of the light chain is shown as SEQ ID NO: 1.Type: ApplicationFiled: March 25, 2011Publication date: December 12, 2013Applicant: HEFEI TAIRUI BIOTECHNOLOGY CO., LTDInventors: Yanwen Jin, David Weaver, Michael Rynkiewicz, Cheng Cao
-
Publication number: 20130330344Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of human OX40, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.Type: ApplicationFiled: August 22, 2013Publication date: December 12, 2013Applicant: UCB PHARMA S.A.Inventors: ALASTAIR DAVID GRIFFITHS LAWSON, ANDREW MALCOLM NESBITT, ANDREW GEORGE POPPLEWELL, STEVAN GRAHAM SHAW, DIANA SHPEKTOR, YI ZHANG
-
Publication number: 20130330772Abstract: Monoclonal antibodies that bind and inhibit activation of epidermal growth factor receptor related member ErbB3/HER3 are disclosed. The antibodies can be used to treat cell proliferative diseases and disorders, including certain forms of cancer, associated with activation of ErbB3/HER3.Type: ApplicationFiled: June 17, 2013Publication date: December 12, 2013Inventors: Sylvie Vincent, William M. Winston, JR., Fang Wang, Solly Weiler, Kristan Meetze, Lyne Breault, Steve Bottega, Ting Chen, Michael DePrima, Christina Fleet, Steven Tyler, Jin-Kyeung Woo, Jeno Gyuris
-
Patent number: 8603466Abstract: The invention provides antibodies that bind the thyroid stimulating hormone receptor (TSHR), especially in humans, and their uses in diagnostic and therapeutic roles. The invention also provides hybridomas for producing such antibodies.Type: GrantFiled: March 29, 2007Date of Patent: December 10, 2013Assignee: King's College LondonInventors: Jasvinder-Paul Singh Banga, Jacqueline Ann Gilbert, Deborah Dunn-Walters, Carolyn Padoa
-
Publication number: 20130316450Abstract: Isolated antibodies that specifically bind the human MET Receptor and inhibit MET signaling are described. Also described are methods of treating cancer, the methods comprising administering a therapeutically effective amount of the provided MET antibodies and combinations thereof.Type: ApplicationFiled: May 10, 2013Publication date: November 28, 2013Applicant: OncoMed Pahrmaceuticals, Inc.Inventors: Edward Thein Htun VAN DER HORST, Aaron Ken SATO
-
Publication number: 20130302353Abstract: The present invention relates to a binding compound which binds to human APRIL. More specifically the invention provides, compositions of anti-APRIL specific antibodies and methods to use such antibodies in modulating the biological activity APRIL, particularly in inflammatory diseases, inhibition of cell proliferation and cancer.Type: ApplicationFiled: March 11, 2013Publication date: November 14, 2013Applicant: BIONOVION HOLDING B.V.Inventors: Jan Paul Medema, Hans Van Eenennaam, Marco Guadagnoli, Fiona Clare Kimberley, Uyen Truong Phan